- The pace of companies' transitions to intelligent automation
is accelerating: 60% are looking to explore new usage or increase
their usage of advanced technologies over the next 18
months.
- Today, while more than 75% of organizations claim they now
already use "some" form of advanced automation (harnessing
AI/machine learning), only 8% have applied next-gen capabilities in
"all" or "most" processes.
- Overcoming integration challenges will be key to new
progress, which from a Safety perspective for many companies is
linked to being able to harness reliable Real-World Data.
BOSTON, May 8, 2024
/PRNewswire/ -- ArisGlobal, an innovative life sciences
technology company and creator of LifeSphere®, has unveiled a
compelling trend among pharmaceutical organizations in its latest
2024 Industry Survey Report. The Report highlights a resolute
commitment to embrace artificial intelligence (AI) to revolutionize
their Safety and Regulatory process automation.
Amid rising ambitions to bring important new drugs to market
cost-efficiently and without delay, 60% of companies plan to
explore adoption or increase usage of advanced technologies over
the next 18 months, according to new research published in
ArisGlobal's 2024 Industry Survey Report1.
The international survey reveals that there is currently a
pronounced gap between Life Sciences organizations' intentions and
their actual use of next-generation technologies. Although more
than 75% of organizations now claim to use some form of 'advanced
automation' within their processes, only 8% have applied
next-generation capabilities on a widespread basis.
To date, difficulty integrating the technology into existing
infrastructure has proved a significant barrier. While the most
substantial blocker to AI adoption in life sciences is budget
(cited by 54% of participating organizations), over a third (36%)
point to poor integration with existing technology. More than
two-thirds (68%) of respondents have found it "very difficult" or
"somewhat difficult" to integrate automation technology with other
systems and/or data.
Overcoming such barriers will be important if companies want to
benefit from new opportunities that emerge from fully leveraging
next-generation technologies. For example, to utilize the full
potential of real-world data (RWD) for critical but labor-intensive
processes – including safety signal detection and validation -
organizations must lean into new technologies. This capability is
now becoming an affordable and accessible option for the
industry.
The ArisGlobal study identified a growing appetite to harness
RWD where possible, to unlock the next level of patient treatment
innovation. Just over half (51%) of organizations are already
connected to some form of RWD, of which 54% expressed plans to
increase the data's usage. For those not yet connected to RWD, 20%
are in the process of connecting to such resources or plan to do so
within the coming 18 months.
Commenting on the industry's soaring ambitions to harness AI and
machine learning as part of everyday safety and regulatory
processes, Emmanuel Belabe, SVP, Customer Success at ArisGlobal
said: "The pace of companies' transitions to intelligent
automation will continue to accelerate due to business and
operational mandates, and because end-to-end, AI-enabled R&D
process automation is becoming much more accessible. This is, to a
large degree, thanks to cloud platforms like LifeSphere® from
ArisGlobal, which is powered by our NavaX advanced automation
engine. For more than 35 years, we've collaborated with top pharma
companies to keep them ahead of what's possible, both internally
with our advanced technology, and through strategic alliances – for
instance, with real-world data providers."
The full ArisGlobal 2024 Industry Survey Report, Life
Sciences R&D Transformation: Ambitions for Intelligent
Automation & Today's Reality, is available for download
at
https://www.arisglobal.com/industry-report-2024/
About ArisGlobal
ArisGlobal, an innovative life
sciences technology company and creator of LifeSphere®, is
transforming the way today's most successful life sciences
companies develop breakthroughs and bring new products to market.
Headquartered in the United
States, ArisGlobal has regional offices in Europe, India, Japan,
and China. For more updates,
follow ArisGlobal on LinkedIn. www.arisglobal.com.
1 ArisGlobal 2024 Industry Survey Report: Life
Sciences R&D Transformation: Ambitions for Intelligent
Automation & Today's Reality
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-momentum-in-pharma-automation-arisglobals-2024-industry-survey-report-highlights-surge-in-ai-powered-safety--regulatory-processes-302139760.html
SOURCE ArisGlobal